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Abstract
Although the epidemiology of methicillin-resistant Staphylococcus aureus (MRSA) varies across Europe, healthcare-associated MRSA
infections are common in many countries. Despite several national guidelines, the approach to treatment of MRSA infections varies
across the continent, and there are multiple areas of management uncertainty for which there is little clinical evidence to guide prac-
tice. A faculty, convened to explore some of these areas, devised a survey that was used to compare the perspectives of infection
specialists from across Europe on the management of MRSA infections with those of the faculty specialists. The survey instrument, a
web-based questionnaire, was sent to 3840 registered delegates of the 19th European Congress of Clinical Microbiology and Infec-
tious Diseases, held in April 2009. Of the 501 (13%) respondents to the survey, 84% were infection/microbiology specialists and 80%
were from Europe. This article reports the survey results from European respondents, and shows a broad range of opinion and
practice on a variety of issues pertaining to the management of minor and serious MRSA infections, such as pneumonia, bacteraemia,
and skin and soft tissue infections. The issues include changing epidemiology, when and when not to treat, choice of treatment, and
duration and route of treatment. The survey identified areas where practice can be improved and where further research is needed,
and also identified areas of pan-European consensus of opinion that could be applied to European guidelines for the management of
MRSA infection.
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Methicillin-resistant Staphylococcus aureus (MRSA) is a
common cause of healthcare-associated infections and a
major problem in hospitals and intensive-care units (ICUs)
worldwide. MRSA is associated with a wide range of infec-
tions, including skin and soft tissue infections (SSTIs), pneu-
monia, bacteraemia, endocarditis, osteomyelitis, prosthetic
joint infections, and catheter-related infections [1,2]. The
past decade has seen an increase in the incidence of MRSA
in hospital settings in Europe [3], and more recently the
emergence of community-acquired MRSA (CA-MRSA). The
proportion of S. aureus infections due to MRSA varies
among countries in Europe, ranging from <1% in the north
to >50% in the south, and rates above 60% have been
reported in some ICUs [3]. Recently, however, several
European countries have seen a decline in the prevalence of
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healthcare-associated MRSA (HCA-MRSA) infections,
possibly reflecting the effect of improved efforts in infection
control, antimicrobial stewardship, and management involve-
ment [4].
The successful management of MRSA infections depends
on making appropriate clinical decisions about the site and
severity of infection, likely antibiotic susceptibility of the
pathogen, indication for surgery and/or antibacterial therapy,
and, if the latter is chosen, type and length of antibacterial
therapy [5]. Management decisions must also take into con-
sideration the removal of possible sources of infection, e.g.
indwelling device, foreign body, or abscess, that can influence
the efficacy of antibiotic therapy.
Several reviews, consensus statements and guidelines have
been published recently to address aspects of the diagnosis
and treatment of MRSA infections in the USA [6–9], Canada
[10], and some European countries [11–15], but a broad
consensus for Europe has been lacking. To address this gap,
a consensus conference sponsored by the European Society
of Clinical Microbiology and Infectious Diseases in 2007
covered selected aspects of the prevention, control and
management of MRSA infections [16], including a review of
available antibiotics [5]. However, many questions on the
most appropriate approach to treatment of MRSA infections
remain unresolved, and there are a number of practical
aspects of management of MRSA infections for which there
is simply no published evidence.
Therefore, a faculty of infection specialists was convened
to address some of these questions through the develop-
ment of a questionnaire that could be used to survey infec-
tion specialists across Europe, with the awareness that there
may be no single answer to some of these questions, and
recognizing that single solutions may not be applicable to
practice in every European country. The aims of the survey
were to explore opinion and exchange ideas, to provide a
broad base of opinion on a variety of issues pertaining to the
management of MRSA infection from infection specialists
across Europe, and to compare those responses with those
of the faculty specialists. It was hoped that the survey might
determine whether the creation of pan-European MRSA
infection management guidelines was practical and, if so,
inform the development of those guidelines with conclu-
sions/recommendations based on the answers to each ques-
tion.
This article reports the findings of the survey, which
targeted a variety of issues pertaining to the management
of MRSA infections, including changing epidemiology, when
and when not to treat, choice of treatment, duration and
route of treatment, and treatment of minor or serious
infections.
Materials and Methods
MRSA workshops and development of the MRSA survey
An expert faculty was chosen by the Chair to represent sev-
eral European countries and to include leaders in infectious
diseases, intensive care and clinical microbiology with experi-
ence in the development of country-specific guidelines. The
faculty met in two workshops in London, UK, and Washing-
ton DC, USA, in September and October 2008, to identify
areas where discussion on management strategies was
needed and to develop a list of controversial or commonly
asked questions on the antibiotic treatment of MRSA
infections.
In the first workshop, the faculty identified key topics, and
members were each assigned a topic for review, based on
their areas of expertise. Faculty members were instructed to
prepare the following for the second meeting: background
information on their topics; challenging or controversial
issues in those topics (e.g. which oral combination treatment
is preferred or what duration of therapy is optimal); and four
or five questions. During the second meeting, members pre-
sented their topics, issues, and questions. The questions
were reviewed and edited by the faculty, and possible
answers to the questions were discussed.
After the workshops, the Chair collated a final list of 30
predefined questions and responses that was circulated to all
the faculty members for their agreement on inclusion in the
survey. Response formats varied, with some questions asking
respondents to select the most preferred option from among
a list, others to select the top three options from among a list,
and some to select any or all options from among a list.
Survey administration. The questionnaire was administered via
the Internet using software developed by an online vendor,
Survey Monkey (http://www.surveymonkey.com). All respon-
ses were anonymous.
Each faculty member was sent an E-mail from the Chair,
introducing the survey and providing a weblink and pass-
word. To survey European specialists, an E-mail invitation to
participate in the survey was sent on behalf of the Chair to
all registered delegates of the 19th European Congress of
Clinical Microbiology and Infectious Diseases (ECCMID; held
on 16–19 May 2009) on 16 and 29 April 2009, again provid-
ing a weblink and password. Delegates were asked to answer
the questions on the basis of their personal opinion and
practice.
Analysis. Simple counts and proportions were calculated for
the survey responses. These were based on the number of
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respondents answering each question. Not all respondents
answered each question.
Results
Demographic characteristics of participants
A total of 13 faculty members participated in the workshops
and voted on their preferred responses to the questions. Of
the faculty members, ten (77%) were hospital-based physi-
cians specializing in infection or critical care, and three (23%)
were laboratory-based infection specialists; all were from
Europe (UK, three; Italy, three; The Netherlands, two;
France, one; Spain, one; Croatia, one; Greece, one; and Tur-
key, one).
The E-mail invitation to participate in the survey was sent
to 3840 registered delegates, and 501 (13%) responded. Two
initial survey questions (Questions 1 and 2) requested the
specialties and countries of work of the participants (Table 1).
The specialties of the respondents included infectious dis-
eases (54%), laboratory microbiology (30%), intensive care
(3%), pharmacology (3%), and respiratory disease (1%), and
the majority of respondents (80%) were from Europe. This
article reports the survey results for European respondents
only (n = 381).
Survey questions and responses
Epidemiology of MRSA
Question 3. If true community-acquired MRSA infection
becomes more common in Europe, do you think that this
will alter empirical antibiotic choices for community-acquired
staphylococcal infection?
Background. True CA-MRSA has not yet become prevalent
in Europe in the same way that it has in the USA [2]. How-
ever, there is modest evidence that the epidemiology is
changing in Europe [17,18]. If this occurs, physicians treating
minor staphylococcal infections in the community will need
to consider whether their choice of empirical antibiotic ther-
apy needs to have activity against MRSA. Such choices will
depend on local sensitivities, but may include older agents
such as doxycycline/minocycline, co-trimoxazole, and clinda-
mycin, and newer oral agents, such as fluoroquinolones with
enhanced Gram-positive activity (moxifloxacin and levofloxa-
cin) and linezolid.
Responses. The majority of the faculty members (92%) and
ECCMID delegates (88%) agreed that empirical antibiotic
choices for community-acquired staphylococcal infection will
be affected by an increased prevalence of CA-MRSA in Eur-
ope (Fig. 1)
Conclusions. Empirical choices of antibiotics for community-
acquired staphylococcal infections may need to be changed
in the future if CA-MRSA becomes more common. The
choice should be based on local surveillance data.
Presentation of MRSA infection
Question 4. Which is the most frequent infection caused by
MRSA in your practice?
TABLE 1. Demographic characteristics of the European
Congress of Clinical Microbiology and Infectious Diseases
survey respondents (Questions 1 and 2)
Characteristic No. (%) of respondents
Specialtya N = 474
Infectious diseases 254 (54)
Laboratory-based microbiology 144 (30)
Other 54 (11)
Pharmacy/pharmacology 16 (3)
Intensive care 14 (3)
Surgery 8 (2)
Respiratory disease 6 (1)
Primary care 4 (<1)
Haematology/oncology 3 (<1)
Geographical region N = 479
Europe 381 (80)
Western Europe 120/381 (32)
Northern Europe 112/381 (29)
Southern Europe 96/381 (25)
Eastern Europe 53/381 (14)
North/South America 28/479 (6)
Australia/New Zealand 15/479 (3)
Other (Asia, Middle East, Africa) 55/479 (11)
aParticipants could choose more than one specialty.
European regions were defined according to the United Nations Statistics Divi-
sion, and included participants from western Europe (Austria [8], Belgium [17],
France [15], Germany [22], Monaco [1], The Netherlands [36], Switzerland
[21]), northern Europe (Denmark [5], Estonia [6], Finland [22], Iceland [2], Ire-
land [10], Latvia [2], Lithuania [1], Norway [2], Sweden [6], the UK [56]), south-
ern Europe (Albania [4], Andorra [2], Croatia [3], Cyprus [1], Greece [12], Italy
[22], Macedonia [2], Malta [3], Portugal [11], Serbia [2], Slovenia [4], Spain [22],
Turkey [8]) and eastern Europe (Bulgaria [3], Czech Republic [12], Hungary [7],
Poland [7], Romania [9], Russia [7], Slovakia [7], and Ukraine [1]).
FIG. 1. If true community-acquired MRSA infection becomes more
common in Europe, do you think that this will alter empirical antibi-
otic choices for community-acquired staphylococcal infection? (Ques-
tion 3.) ECCMID, European Congress of Clinical Microbiology and
Infectious Diseases; MRSA, methicillin-resistant Staphylococcus aureus.
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Background. MRSA behaves in a way similar to sensitive
strains of S. aureus in its ability to cause a remarkable spec-
trum of pathology [19]. S. aureus usually causes localized
SSTIs in which entry is via a hair follicle (boil, furuncule, car-
buncle, or folliculitis), impetigo, or wound. S. aureus is one of
the most common isolates from blood cultures and there-
fore a major cause of bloodstream infections. Community-
acquired staphylococcal bloodstream infections probably gain
entry via minor breaks in the skin, whereas hospital-acquired
staphylococcal bacteraemia occurs most frequently via intra-
vascular catheters. Bacteraemia can infect many organs in the
body, resulting in, for example, osteomyelitis, septic arthritis,
vertebral osteomyelitis/discitis, myositis and deep muscle
abscesses, endocarditis, or pneumonia; staphylococcal pneu-
monia can also arise from aspiration, often following a viral
pneumonitis, especially influenza [20].
Responses. This question was chosen to survey the respon-
dents’ clinical experience in MRSA infection. SSTI was the
most frequent MRSA infection seen in European clinical prac-
tice, as reported by 79% of ECCMID delegates and 39% of
faculty members (Fig. 2). However, a large proportion (39%)
of the faculty members also reported that bloodstream infec-
tion was the most common infection caused by MRSA in
their practice. This difference in distribution probably reflects
the fact that the members of the faculty are highly specialized
and from tertiary-care centres, seeing a more selective
patient population than that of the overall group of respon-
dents.
Conclusions. The ECCMID delegates and faculty members
were seeing a wide range of presentations of MRSA infec-
tion, of which SSTI was the most common. MRSA causes the
same range of infections as methicillin-sensitive Staphylococcus
aureus (MSSA). In institutions where there is a higher
carriage rate of MRSA, deep-seated and bloodstream infec-
tions with MRSA may be more common.
Question 5. Which is the most common focus of MRSA
bloodstream infections in your practice?
Background. Most MRSA bacteraemia in Europe is health-
care-associated. Several studies [21,22] have demonstrated
that the most common foci for MRSA bacteraemia are intra-
vascular catheters—those sited in peripheral vessels, as well
as those sited centrally. Even if the patient presents to hospi-
tal with an MRSA bacteraemia, the focus is often related to a
vascular catheter sited at a recent hospital visit. Other com-
mon foci are skin and soft tissue sites—especially ulcers,
chronic wounds, or surgical wounds—and the urinary tract
in association with urinary catheters.
Data from the MRSA bacteraemia Enhanced Surveillance
Scheme provide an important means of identifying risk fac-
tors and sources of bacteraemia in British patients [22].
SSTIs (the most common sources of bacteraemia in the
admission-diagnosed group) may result from the use of
peripheral intravascular devices, the most common risk fac-
tor in this group. It is hypothesized that a large proportion
of those patients presenting to the acute hospital with an
MRSA bacteraemia developed this condition as a result of a
prior healthcare contact. Identification of key risk factors
and sources of bacteraemia will allow effective targeting of
infection control interventions and help guide selection of
initial empirical antibacterial therapy.
Responses. In the survey, 48% of ECCMID delegates listed
intravascular lines as the most common foci of bloodstream
infections (Fig. 3). These sources therefore represent a
major target for healthcare intervention in the reduction of
serious MRSA infection across Europe. Careful management
of intravascular lines is an effective intervention in reducing
bloodstream infections. Skin and soft tissue was reported by
31% of respondents as the most common focus of bactera-
emia (Fig. 3). As the great majority of MRSA bloodstream
infections in Europe are healthcare-related, the sources of
many of these infections are likely to be surgical wounds.
Preventing these also represents a target for reducing the
number of MRSA bloodstream infections, and the obvious
method for this is the screening of surgical patients for
MRSA and, if necessary, subsequent decolonization therapy
[23,24].
The fact that 13% of ECCMID delegates and one faculty
member reported respiratory tract infection as the most
common focus for MRSA bacteraemia is surprising. Staphylo-
coccal pneumonia is relatively rare. Even in ventilated patients
in high-dependency units, the finding of staphylococci,
FIG. 2.Which is the most frequent infection caused by MRSA in
your practice? (Question 4.) ECCMID, European Congress of Clini-
cal Microbiology and Infectious Diseases; MRSA, methicillin-resistant
Staphylococcus aureus.
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especially MRSA, in respiratory secretions usually represents
colonization rather than infection.
Conclusions. Healthcare organizations should optimize the
care of intravascular catheters by ensuring insertion under
aseptic conditions, documentation in the patient records,
daily inspection of the catheter site, and removal as soon as
possible. Decreasing the frequency of catheter use is also
important. Surgical wound infection with MRSA can be
reduced by preoperative screening for MRSA and, if neces-
sary, decolonization therapy.
Clinical decision-making and empirical therapy
Question 6. Would you prescribe antibiotics active against
MRSA in the following situations? (Check all that apply.)
Background. Knowing when to treat for MRSA can be
challenging for practising clinicians. Serious MRSA sepsis can
be life-threatening, and requires expedient and aggressive
management, including treatment with an appropriate antibi-
otic with known activity against MRSA. On the other hand,
inappropriate second-line or broad-spectrum antibiotics can
be costly and can engender the development of antimicrobial
resistance.
This means that the prescribing physician must be aware
of the local epidemiology and particular risk factors for
MRSA infection. These are not the same in every geographi-
cal area across Europe [18].
Responses. Not surprisingly, the responses were varied
(Table 2). Nearly all of the faculty members and ECCMID
delegates agreed with the statement that significant MRSA
bacteraemia should be treated—when MRSA is isolated
from the blood and the patient has clinical signs compatible
with sepsis—with antibiotics active against MRSA. A pro-
portion of the ECCMID delegates would treat what most
would regard as colonization rather than infection: 8% for
MRSA in catheter urine, 19% for MRSA in a chronic ulcer,
and 16% for MRSA in sputum with no new chest signs.
Systemic antibiotics would not be recommended for colo-
nization. Twenty-two per cent would use antimicrobials
effective against MRSA to treat a patient with an uncompli-
cated wound infection; this is appropriate practice.
Twenty-five per cent would use antibiotics effective against
MRSA to treat a patient with no comorbidities but who
had a deep abscess with Gram-positive cocci on Gram
stain; this decision must rely on local epidemiology. Many
more, 61%, would use treatment active against MRSA
when the deep abscess was in a patient with risk factors
for MRSA, such as diabetes and regular hospital admission.
Conclusions. Where there is colonization but not infection,
systemic antibiotics should not be used, except, rarely, as a
part of a decolonization attempt (in combination with
local treatment) in a complicated carrier. If local risk
factors—particularly previous colonization with MRSA—and
FIG. 3.Which is the most common focus of MRSA bloodstream
infections in your practice? (Question 5.) ECCMID, European Con-
gress of Clinical Microbiology and Infectious Diseases; IV, intrave-
nous; MRSA, methicillin-resistant Staphylococcus aureus.
TABLE 2. Would you prescribe
antibiotics active against MRSA in
the following situations? (Check all










Significant MRSA bacteraemia, i.e. MRSA isolated from blood culture
and patient has clinical signs compatible with sepsis
12 (100) 299 (99)
MRSA isolated in catheter urine in a patient who is otherwise well 0 25 (8)
MRSA isolated in minor (uncomplicated) wound infection in a patient
who is otherwise well
2 (17) 66 (22)
MRSA in a chronic venous ulcer in a patient who is otherwise well 3 (25) 58 (19)
Gram-positive cocci in clusters from deep soft tissue abscess in a
patient with no comorbidities from the community
2 (17) 75 (25)
Gram-positive cocci in clusters from deep soft tissue abscess in a
diabetic patient with regular hospital admission from the community
6 (50) 185 (61)
MRSA in sputum of patient with chronic obstructive airways disease,
and no new chest signs
0 47 (16)
ECCMID, European Congress of Clinical Microbiology and Infectious Diseases; MRSA, methicillin-resistant Staphy-
lococcus aureus.
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epidemiology suggest a significant risk for MRSA being a path-
ogen in a clinical infection, empirical treatment should include
coverage against MRSA.
Question 7. Would any of the following risk factors make
you start empirical therapy against MRSA for a patient with
suspected bacteraemia presenting as an emergency?
Background. Delay in the administration of adequate antimi-
crobial treatment to critically ill patients with MRSA blood-
stream infections increases the risk of mortality associated
with these infections [25]. Thus, it is important for clinicians
working in hospitals and emergency departments to realize
the importance of instituting appropriate therapy early when
there is a significant likelihood of MRSA infection. This reali-
zation depends upon knowing the local epidemiology of, and
risk factors for, MRSA infection.
Responses. In general, the faculty members were more
likely than the ECCMID delegates to start empirical ther-
apy against MRSA infection if key risk factors for MRSA
infection were present (Table 3). However, the majority
of both groups agreed that they would start empirical
therapy active against MRSA for an ill patient with sus-
pected bacteraemia who had previously been colonized
with MRSA. A minority of the faculty members (15%) and
ECCMID delegates (31%) stated that they would not start
empirical therapy against MRSA until cultures were positive
for MRSA.
Conclusions. The main risk factor for MRSA infection is
prior colonization. Empirical treatment covering MRSA
should be strongly considered in bacteraemic patients known
to be colonized with MRSA. Screening for MRSA and decolo-
nization should be performed in regular attenders of health-
care facilities. Other risk factors may be important in certain
locations. Therefore, a decision on commencing empirical
treatment to cover MRSA in a patient with suspected bacter-
aemia with any of the other listed risk factors must be based
on local epidemiology.
Oral antibacterial therapy
Question 8. Are oral antibiotics ever justified for the initial
treatment of proven MRSA infection in the following? (Check
all that apply.) (Fig. 4.)
Background. It is a common belief that systemic infections
should be treated with parenteral antibiotics. However, it
has been established that some severe infections can be trea-
ted at home with oral antibiotics just as effectively as with
parenteral therapy in hospitals [26–28]. Oral therapy offers
the advantage of increased comfort for the patient and saved
resources for the healthcare system through reduced fre-
quency of admission to hospital. Staphylococcal infections
are generally considered to be serious, with the potential to
cause metastatic infections with a high mortality rate. Oral
agents should have good bioavailability. High doses of antimi-
crobials used orally may be necessary to ensure adequate
concentrations of the drug at the infection site. In addition,
patients need to absorb the drug, and oral therapy should
not be used in patients who are vomiting or who have
severe diarrhoea. There is a need to further define the role
of oral therapy in staphylococcal infections, especially those
caused by MRSA.
Responses. The majority of faculty members (92%) and
ECCMID delegates (86%) agreed that oral antibiotics can be
used for the treatment of uncomplicated, non-serious SSTIs
due to proven MRSA (Fig. 4). Faculty members were more
likely than ECCMID delegates to also consider use of oral
antibiotics for the treatment of proven MRSA in complicated
TABLE 3. Would any of the following risk factors make you
start empirical therapy against MRSA for a patient with
suspected bacteraemia presenting as an emergency? (Check










Previous use of quinolones 6 (46) 55 (18)
Previous use of macrolides 2 (15) 19 (6)
Previous MRSA colonization 12 (92) 218 (72)
Previous hospital admission within 3 months 9 (69) 104 (34)
Admitted from nursing home 9 (69) 87 (29)
Foreign-body infection 9 (69) 109 (36)
I would not start empirical anti-MRSA
treatment until cultures were positive for
MRSA
2 (15) 95 (31)
ECCMID, European Congress of Clinical Microbiology and Infectious Diseases;
MRSA, methicillin-resistant Staphylococcus aureus.
FIG. 4. Are oral antibiotics ever justified for the initial treatment of
proven MRSA infection in the following? (Check all that apply.)
(Question 8.) ECCMID, European Congress of Clinical Microbiology
and Infectious Diseases; MRSA, methicillin-resistant Staphylococcus
aureus.
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SSTIs and bone and joint infections. A significant proportion
(25%) of the faculty members and ECCMID delegates would
consider use of oral agents for the treatment of pneumonia,
whereas only 10% would consider oral agents for treatment
of MRSA bacteraemia.
Conclusions. Oral treatments with antibiotics that have
good bioavailability are appropriate for many MRSA infec-
tions, especially SSTIs and bone and joint infections. Such
drugs could also be considered in bloodstream infections and
pneumonia when the clinical condition is stabilizing.
Question 9. If oral drugs are acceptable, which oral treat-
ment would you consider for the initial treatment of serious
MRSA infection, providing that the isolate is susceptible to
the drug?
Background. The choice of orally available antibiotics with
in vitro activity against MRSA includes co-trimoxazole
(trimethoprim–sulphamethoxazole), clindamycin, doxycycline
and minocycline, linezolid, rifampicin, fusidic acid and
occasionally quinolones [29–32]. These agents are used
alone or in combination (see Question 17). CA-MRSA is
more likely to be sensitive to a wider range of these anti-
biotics than is hospital-acquired MRSA (HA-MRSA). There
is concern that some of the antibiotics active against MRSA
in vitro may be ineffective or only sporadically effective
in vivo [33]. There is a lack of well-designed, controlled
studies for the treatment of staphylococcal infections with
some of the older antibiotics, which further complicates
the decision on whether to use these antibiotics [34].
Responses. Linezolid was the most common oral choice for
the initial, empirical treatment of serious MRSA infection,
selected by the faculty members and by 68% of the ECCMID
delegates who considered oral drugs to be acceptable
(Fig. 5). Co-trimoxazole (trimethoprim–sulphamethoxazole),
doxycycline plus rifampicin or fusidic acid, rifampicin plus
fusidic acid, and clindamycin plus rifampicin were also
selected by 24–55% of the faculty members. Other choices,
including moxifloxacin–levofloxacin combination therapy and
doxycycline monotherapy, were selected by fewer than 20%
of the ECCMID delegates.
Conclusions. Oral linezolid is considered to be appropriate
oral treatment for serious MRSA infection. Other oral
agents—usually in combination, such as doxycycline plus
rifampicin or fusidic acid, clindamycin plus rifampicin, and co-
trimoxazole—are used, depending on susceptibility results.
Question 10. Which of the following criteria are important
for an early switch from intravenous (IV) to oral adminis-
tration in a patient with MRSA infection able to take oral
medication?
Background. When a suitable oral agent exists, IV-to-oral
switch programmes have been shown to be highly effective
for a variety of infections [35–37]. The criteria for IV-to-oral
switch, as well as the success of discharging patients from
hospital on oral therapy for many infections, including
serious Gram-positive infections, are well established
[38–39]. Criteria specific for serious Gram-positive infections
have been suggested by Desai et al. [39]. Among patients
receiving IV glycopeptide for antimicrobial-resistant Gram-
positive infections of the blood, sputum, skin, soft tissue, and
other sites, criteria were used to identify those who could
be potentially discharged on oral medication. This would
clearly have many benefits, such as reduced need for IV
access or reduction in hospital length of stay, without
compromising safety.
Although many suitable patients may be identified, for
MRSA infections there remains a general reluctance among
clinicians to discharge patients on oral medication; this may
reflect a lack of clarity of the criteria used for IV-to-oral
switch, or a lack of confidence in oral therapy for serious
infections.
Responses. There was broad agreement (>60%) between
the faculty members and ECCMID delegates about the crite-
ria for switching from IV to oral therapy for MRSA infections
(Table 4). The site of infection, clinical stability and reduction
in C-reactive protein levels were common criteria used in
this decision. Both groups attached less importance to a nor-
mal white blood cell count (WBC) as a criterion for IV-to-
oral switch.
Clinical stability (defined by a temperature of <38C for
24 h, normalizing WBC, and no unexplained tachycardia
FIG. 5. If oral drugs are acceptable, which oral treatment would you
consider for the initial treatment of serious MRSA infection, provid-
ing that the isolate is susceptible to the drug? (Check all that apply.)
(Question 9.) ECCMID, European Congress of Clinical Microbiology
and Infectious Diseases; MRSA, methicillin-resistant Staphylococcus
aureus.
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(heart rate of <100 beats/min)), known antimicrobial sensitiv-
ity (if the pathogen has been identified by the microbiology
laboratory), adequate oral absorption (defined as the
patient’s ability to tolerate oral fluids), no medical problems
leading to reduced absorption, and no surgical operation
scheduled within the next 36 h are typical factors used to
identify patients suitable for IV-to-oral switch [39]. Insisting
on a normal WBC does not appear to influence the effec-
tiveness of the switch. These criteria offer clinicians objective
guidance and reassurance when they are considering switch-
ing patients from IV to oral therapy in the management of
MRSA infections.
Conclusions. IV-to-oral switch appears to be safe for a vari-
ety of infections, with benefits for both the patient and the
hospital. It is appropriate once there is clinical stability and a
resolving infection site. The optimal duration of therapy
remains uncertain, and requires further investigation.
Duration of antibacterial therapy
Question 11. What is your minimum total duration of ther-
apy in MRSA bacteraemia due to a line infection if the line
has been removed and there is no evidence of another focus
(e.g. endocarditis)?
Background. Historically, all patients with S. aureus bactera-
emia were given treatment with long courses (4–6 weeks) of
therapy, largely because of concerns that endocarditis or
other complications might be present but undiagnosed. Ret-
rospective studies performed in the early 1990s suggested
that 10–14 days of therapy was appropriate for patients with
catheter-associated S. aureus bacteraemia in the absence of
clinical evidence of early metastatic complications [40,41]. In
a meta-analysis performed to address the efficacy of short-
course therapy for catheter-associated S. aureus bacteraemia,
the authors concluded that short-course therapy could not
be recommended until a means existed to identify ‘low-risk’
patients [42]. A more recent post hoc analysis of a random-
ized clinical trial of patients with S. aureus bacteraemia and
infective endocarditis examined the effect of duration of
therapy on outcomes. Success rates among patients who
received <14 days of antibiotic therapy were significantly
lower than those among patients who received a longer
duration of therapy (Boucher et al., 46th ICAAC, 2006,
Abstract L-1204). Mortality was also associated with an anti-
biotic course <14 days in duration [43]. In a study specifically
looking at catheter-related staphylococcal bacteraemia,
courses of antibiotics lasting for <10 days were associated
with relapse. Persisting fever at 3 days suggested a compli-
cated course requiring further investigation and prolonged
treatment [41].
Responses. Whereas all faculty members selected 10 or
14 days as the minimum duration of therapy for bacteraemia
due to MRSA (Fig. 6), there was little consensus among the
ECCMID delegates, suggesting that many patients with MRSA
bacteraemia are being inadequately treated. This survey find-
ing has important educational consequences for physicians
managing staphylococcal bacteraemia.
Conclusions. For uncomplicated MRSA bacteraemia due to a
line infection, current guidelines and evidence support the
minimum recommended treatment duration of 10–14 days.
Repeat blood cultures should be collected on day 3 of treat-
ment, along with investigation of the foci. MRSA bacteraemia
TABLE 4. Which of the following criteria are important for
an early switch from IV to oral in a patient with MRSA











Clinical improvement, and no
evidence of hypotension or shock
11 (85) 193 (72)
Site of infection 10 (77) 191 (72)
No temperature for 24 h 10 (77) 150 (56)
Falling inflammatory markers
(e.g. CRP)
9 (69) 176 (66)
Normal WBC count 5 (39) 68 (26)
CRP, C-reactive protein; ECCMID, European Congress of Clinical Microbiology
and Infectious Diseases; IV, intravenous; MRSA, methicillin-resistant Staphylococcus
aureus; WBC, white blood cell.
FIG. 6.What is your minimum total duration of therapy in MRSA
bacteraemia due to a line infection if the line has been removed and
there is no evidence of another focus (e.g. endocarditis)? (Ques-
tion 11.) ECCMID, European Congress of Clinical Microbiology and
Infectious Diseases; MRSA, methicillin-resistant Staphylococcus aureus.
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with complications may require prolonged courses of
antibiotics in addition to further investigation and possible
surgical intervention at the foci of infection. A significant pro-
portion of respondents are using shorter courses of antimi-
crobials, suggesting a need for education around investigation
of sources of staphylococcal infection and duration of treat-
ment.
Question 12. What do you regard as the optimal total
duration of therapy for MRSA pneumonia?
Background. There are few data on the optimal duration of
antibiotic therapy for HCA-MRSA pneumonia [44–49]. Until
recently, most experts recommended that treatment of nos-
ocomial MRSA pulmonary infections should last for at least
14 days, because of the risk of late-onset complications, such
as abscesses, and a higher risk of relapse with courses of
therapy £14 days [12,46,50–53].
The tendency of MRSA to cause ventilator-associated
pneumonia (VAP) recurrence may reflect the suboptimal
antimicrobial action of vancomycin and its inability to eradi-
cate the bacteria from the respiratory tract, as its penetra-
tion into lung tissue and pulmonary lining fluid is relatively
low [49,54,55].
The recommendation of a prolonged duration of therapy
for MRSA pneumonia remains largely empirical, owing to a
lack of prospective, controlled studies. Unfortunately, this
traditional approach of prolonged antibiotic therapy may
favour the emergence of multidrug-resistant strains of
S. aureus, expose patients to unnecessary antibiotic toxicity,
and increase costs [50,56,57].
In a subset analysis of 42 patients with MRSA who were
included in a large multicentre, randomized controlled trial
comparing two durations of antibiotic therapy for VAP, the
clinical outcomes of patients who received therapy for 8 days
were similar to those of patients who received therapy for
15 days [44].
Thus, prolonging therapy may not by itself prevent com-
plications. Another option is to customize the duration of
antibiotic therapy according to the patient’s clinical status
and their risk factors for an adverse outcome. The feasibility
of basing duration of antibiotic therapy on the patient’s clini-
cal status was evaluated in a prospective, randomized con-
trolled trial of 302 patients with VAP who were randomly
assigned to have the duration of antibiotic therapy deter-
mined either according to an antibiotic discontinuation policy
or by their treating physicians [58]. In the policy group,
recommendations were made to stop antibiotics if the
pulmonary infiltrate was identified as non-infectious, and if
the signs and symptoms suggesting an active infection
had resolved (body temperature £38.3C; leukocyte
count £10 000/lL or ‡25% below peak values; absence of
purulent sputum; improvement or lack of progression on
the chest radiograph; PaO2/FiO2 ‡250). Both groups had simi-
lar clinical outcomes, including hospital mortality, duration of
mechanical ventilation, and proportion experiencing relapse,
although the duration of antibiotic therapy was significantly
shorter in the discontinuation policy group [58]. Unfortu-
nately, only a few patients with MRSA infection were
included in this study, making it difficult to draw a firm con-
clusion for this subset of patients. The value of using specific
risk factors in customizing the duration of antibiotic therapy
remains to be demonstrated. Several clinical and biological
factors have been shown to evolve differently among survi-
vors and non-survivors of VAP [45,46,59–61]. For example,
serial measurements of the modified clinical pulmonary infec-
tion score were able to distinguish among survivors and
non-survivors, starting on day 3 after a diagnosis of VAP in a
cohort of patients managed in Buenos Aires [59]. Of the
individual components of the clinical pulmonary infection
score, only the improvement in PaO2/FiO2 significantly distin-
guished survivors from non-survivors. Other studies have
confirmed these findings [46,61].
Responses. There was lack of consensus on the optimum
duration of therapy for MRSA pneumonia (Fig. 7), although
14 days was selected by 62% of the faculty members and
48% of the ECCMID delegates.
FIG. 7.What do you regard as the optimal total duration of therapy
for MRSA pneumonia? (Question 12.) ECCMID, European Congress
of Clinical Microbiology and Infectious Diseases; MRSA, methicillin-
resistant Staphylococcus aureus.
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Conclusions. The optimum duration of therapy for MRSA
VAP is unknown. Respondents favoured 14 days as an appro-
priate duration.
Factors that influence the selection of antibacterial agents
Question 13. For the management of MRSA infections, what
are the top three factors that most influence your antibiotic
choice? (Check three factors.)
Background. The decision-making process relating to the
use and choice of antibiotics is complex [62]. Some impor-
tant influences and processes were identified when a range
of decision support systems for antibiotic prescribing were
developed [63–65]. These computerized or paper-based sup-
port systems indicate that clinicians value being able to pre-
dict the likely pathogen and effective antibiotics on the basis
of information relating to patient factors, site of infection,
local susceptibility, and pharmacokinetic/pharmacodynamic
requirements. However, at an individual prescriber level, the
extent of interplay between clinical, experiential, pharmaco-
logical, fiscal and other factors is poorly defined and is sub-
ject to many influences [66–69]. Once the diagnosis is made
or confirmed, the clinical effectiveness of the antibiotic for a
particular setting, the availability of microbiological and local
resistance data, the severity and site of infection and patient
factors such as comorbidity or potential for drug interactions
are all considered to be important in the decision of
whether or not to prescribe an antibiotic.
Local guidelines and their availability also appear to inform
this process. For example, a clinical consensus conference
examined the ‘real-world’ management of S. aureus blood-
stream infections through a methodology similar to ours
[70]. In this survey, local epidemiology and individual risk fac-
tors appeared to be the main determinants for the initiation
of empirical MRSA treatment [70], but the determinants for
choice of antibiotic were not explored.
Therefore, a broader understanding of this process for
managing a range of MRSA infections warrants further evalu-
ation, so that researchers and policy-makers developing clini-
cal guidance can inform this process.
Responses. The results indicate, as one would expect, that
the clinical efficacy of the antibiotic was the factor most
frequently chosen by the faculty members and ECCMID dele-
gates as crucial to choosing an antibiotic for managing MRSA
infection (Fig. 8). Antibiotic pharmacokinetics/pharmacody-
namics and individual patient factors, such as age, comorbi-
dity, and previous antibiotic use, were also considered to be
important by the majority of respondents. A smaller
proportion of respondents considered a desire or require-
ment to use local/national formulary guidance as an important
factor in determining antibiotic choice. Potential for drug
interactions, economic advantages (such as reduced length of
stay) and drug cost were considered to be important by
some respondents, whereas patient preference was not.
Severity of illness as a specific factor governing antibiotic
choice was not specifically asked for in the survey, although
comorbility, which was asked for, may be considered as a
surrogate for illness severity.
Conclusions. The top three factors in the choice of an anti-
biotic for treatment of MRSA infection are efficacy, pharma-
codynamic performance, and patient factors. These data
suggest that clinicians value, above all, the clinical efficacy of
an antibiotic combined with its ability to effectively achieve
optimal activity at the site of infection and to be effective in
vulnerable patients with complex comorbidities.
Question 14. For the management of MRSA infections, what
are the top three health economic factors that most influ-
ence your antibiotic choice? (Check three factors.)
Background. Health economic evaluation of the impact of
new therapies is now considered to be an essential compo-
nent of new drug assessment in many countries [71].
Whether these economic evaluations are used at the three
levels of decision-making—central, local, and individual physi-
cian—is uncertain. A systematic review (55 articles) of self-
reported attitudes of healthcare decision-makers regarding
economic evaluations of medical technologies was recently
published [72]. This revealed that, for physicians, 36% of
studies reported economic evaluation as a major influence
on health policy decisions, 57% reported it as a moderate
influence, and 14% reported it as a minor influence. A num-
ber of barriers to the use of economic evaluations in the
FIG. 8. For the management of MRSA infections, what are the top
three factors that most influence your antibiotic choice? (Check
three factors.) (Question 13.) ECCMID, European Congress of Clini-
cal Microbiology and Infectious Diseases; MRSA, methicillin-resistant
Staphylococcus aureus.
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decision-making process were reported. The types of eco-
nomic evaluation undertaken and the outcomes measures
are variable. Commonly reported economic outcomes
include length of stay, quality-adjusted life-years (QALYs),
drug costs, and cost of episode of infection [73–76]. Data on
the economic value of specific antibiotics for a range of
infections have also been published [77]. Currently, these
outcomes are primarily reported from a hospital or payer
perspective [78].
Responses. ECCMID delegates and the faculty members
agreed that reduced length of stay was one of three impor-
tant economic outcomes that were valued in the process of
selecting a treatment for MRSA infections (Fig. 9). Reduced
time in the ICU and duration of IV therapy were also consid-
ered to be important by ECCMID delegates, whereas the
faculty members appeared to give more weight to reducing
overall cost of care for an episode of infection. Despite the
availability of QoL data for VAP in both groups surveyed,
only 30% valued QoL measures such as QALY, presumably
reflecting their perceived uncertain value in acute as opposed
to chronic infections [79].
Conclusions. These responses are of interest to those who
develop policy for treatment of MRSA infections, and who
may want to consider formulary agents that offer healthcare
resource benefits, such as a potential to reduce length of stay
by reducing time on mechanical ventilation for VAP, or reduc-
ing duration of IV therapy—either by early IV-to-oral switch,
or by discharging patients on ambulatory IV therapy. On the
other hand, the impact of antibiotic selection on QALYs may
be deemed to be more valuable in those infections where
there is a medium-term to long-term impact on QoL. QALYs
may also offer a useful means of allowing comparative choices
to be made between different therapeutic approaches.
Outpatient therapy
Question 15. Once the patient is stable, would you con-
sider outpatient parenteral antibiotic therapy (OPAT) for the
management of MRSA infections? (Check all that apply.)
Background. Parenteral antimicrobial therapy is required to
treat a variety of acute, subacute and chronic infections. In
many parts of the world, this treatment is traditionally offered
in the inpatient setting, but the past three decades have seen
an unprecedented increase in the delivery of these therapies in
the non-inpatient setting. This option offers the patient and
those who care for the patient, and hospital-based and com-
munity-based clinicians and administrators, a number of poten-
tial clinical, economic and QoL benefits [80–82].
Recent experience from a 13-year programme in the UK
[83] provides a good example of the range of infections that
are treated effectively in the ambulatory setting. Gram-posi-
tive infections predominate, particularly those associated
with prosthesis and bone and joint infections and compli-
cated SSTIs. A recent European perspective on OPAT also
provides insights into the opportunity that it represents for
managing these infections [84]. However, many barriers to
adopting OPAT have been reported [85].
Responses. The survey confirmed that ECCMID delegates
and faculty members favoured the use of OPAT for managing
bone, joint or prosthetic infections and complicated SSTIs,
although some (approximately 30%) would not use OPAT or
would switch patients to oral medication (Fig. 10).
Conclusions. There is broad support for policy-makers and
clinicians to develop OPAT services for certain infections,
with the goal of improving healthcare resource use, although
FIG. 9. For the management of MRSA infections, what are the top
three health economic factors that most influence your antibiotic
choice? (Check three factors.) (Question 14.) ECCMID, European
Congress of Clinical Microbiology and Infectious Diseases; ICU,
intensive-care unit; IV, intravenous; MRSA, methicillin-resistant Staph-
ylococcus aureus; QALY, quality-adjusted life-year.
FIG. 10. Once the patient is stable, would you consider outpatient
parenteral antibiotic therapy (OPAT) for the management of MRSA
infections? (Check all that apply.) (Question 15.) ECCMID, European
Congress of Clinical Microbiology and Infectious Diseases; IV, intra-
venous; MRSA, methicillin-resistant Staphylococcus aureus. Outpatient
IV therapy is unnecessary because oral switch is usually appropriate.
CMI Dryden et al. Antibiotic management of MRSA: a European survey 13
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16 (Suppl. 1), 3–30
further research is necessary to clearly differentiate between
the clinical and microbiological risks and benefits of oral
therapy as compared with OPAT for these infections.
Antibiotic combination therapy
Question 16. Do you use combination therapy to treat
serious MRSA infection?
Background. Some clinicians advocate the use of combina-
tion therapy for the treatment of serious MRSA infections,
particularly if a polymicrobial infection is suspected and a
broad spectrum of antimicrobial activity is desired. Kollef
recommended combination antimicrobial treatment as a pos-
sible strategy, combined with consultation of infectious dis-
ease specialists and/or the use of antibiotic practice
guidelines to reduce the risk of inadequate antimicrobial
treatment [86]. Furthermore, combining antibiotics could be
considered an efficient way to prevent the development of
antibiotic resistance [87].
Responses. A majority of the faculty members (69%) and
ECCMID delegates (75%) indicated that they would use com-
bination therapy to treat serious MRSA infections (Table 5). It
would therefore seem that practice is following the consider-
ations reported above, but it may also mean that serious
MRSA infections are difficult to treat with monotherapy and
that physicians feel more confident with combination therapy.
Conclusions. See Question 18.
Question 17. In your opinion, how does combination ther-
apy compare with monotherapy for the treatment of serious
MRSA infection? (Check all that apply.)
Background. In vitro kill curves and animal studies have shown
inconsistent synergistic activity of several antibiotic combina-
tions against MRSA and vancomycin-resistant S. aureus. Vanco-
mycin–rifampicin or vancomycin–tigecycline [88], and
vancomycin–gentamicin or vancomycin–tobramycin [89], have
been reported as being effective, although a recent study failed
to confirm this [90]. Vancomycin–nafcillin is also a combina-
tion that is active against MRSA [91]. Recently, the efficacy of
combining rifampicin with vancomycin or daptomycin was
confirmed in a model of MRSA foreign-body infection [92].
Only a few prospective clinical trials have studied combi-
nations of antimicrobials for the treatment of MRSA infec-
tions. For the treatment of endocarditis, vancomycin in
combination with aminoglycosides resulted in more rapid
response and better eradication of infection in valves [93],
but was associated with more toxicity than monotherapy
with daptomycin [94]. The addition of rifampicin to vancomy-
cin has not been shown to shorten the duration of bactera-
emia in the only (small) prospective study of MRSA
bacteraemia or native valve endocarditis performed [95], and
has been associated with hepatotoxicity, drug–drug interac-
tions, and the emergence of resistant S. aureus isolates [96].
Linezolid in combination with rifampin and/or fusidic acid
[97] or carbapenems [98] has been used as salvage therapy
for difficult cases. Combinations of fusidic acid with
b-lactams or rifampicin are widely used in some countries,
although they are poorly studied [99].
Responses. Faculty members and ECCMID delegates were
asked to provide their opinion on how combination therapy
compares with monotherapy for the treatment of serious
MRSA infection (Table 5). Although the majority of the sur-
vey participants indicated that they would use combination
therapy to treat MRSA infections (answered above in Ques-
tion 16), there was little consensus on how it compared with
monotherapy, and it is interesting to note that a higher
percentage of the faculty members (75%) than the ECCMID
delegates (36%) indicated that there is not enough evidence
to justify its routine use.
Conclusions. See Question 18.
Question 18. If combination therapy is acceptable, which
would you consider for serious MRSA infection? (Check all
that apply.)
TABLE 5. Combination antibiotic treatment for methi-








Do you use combination therapy to
treat serious MRSA infection?
N = 13 N = 251
Yes 9 (69) 189 (75)
No 4 (31) 62 (25)
In your opinion, how does combination
therapy compare with monotherapy
for the treatment of serious MRSA
infection? (Check all that apply)
N = 12 N = 242
More effective than monotherapy 3 (25) 97 (40)
Increasing risk of toxicity 5 (42) 77 (32)
Not enough evidence for routine use 9 (75) 87 (36)
Glycopeptides alone do not provide
adequate therapy for serious infection
1 (8) 64 (26)
Less likely for resistance to develop 6 (50) 114 (47)
Combination therapy shortens duration 1 (8) 27 (11)
Other 2 (17) 24 (10)
If combination therapy is acceptable, which
would you consider for serious infection?
(Check all that apply)
N = 9 N = 250
Glycopeptide plus aminoglycoside 4 (44) 82 (33)
Glycopeptide plus rifampicin or fusidic acid 7 (78) 150 (60)
Tetracycline–doxycycline plus rifampicin
or fusidic acid
1 (11) 55 (22)
Daptomycin plus aminoglycoside 0 37 (15)
Linezolid plus aminoglycoside 0 54 (22)
ECCMID survey only: Other – 26 (10)
ECCMID, European Congress of Clinical Microbiology and Infectious Diseases.
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Background. There is little published literature regarding
the use of combination antibacterial therapy for the empirical
treatment of severe MRSA infections. The majority of drugs
active against MRSA provide only anti-Gram-positive activity,
and coverage of potentially present Gram-negative pathogens
is often required in empirical treatment. Hence, the addition
of gentamicin—with activity against both S. aureus and Gram-
negative microorganisms—to glycopeptides is an example of
combination empirical therapy for sepsis, complicated and
severe SSTIs and nosocomial pneumonia in which MRSA and
Gram-negative organisms may be pathogens.
A different situation is the use of combination therapy in
patients with confirmed MRSA monomicrobial infections.
There is no consensus on the superior efficacy of combina-
tion therapy over monotherapy in MRSA infections, with a
few exceptions. The use of vancomycin with rifampin is com-
mon clinical practice in many institutions. However, in vitro
data regarding this combination are contradictory and con-
fusing [100–102], and data obtained in animal models
[103,104] and in humans do not support a conclusion that
the addition of rifampin to vancomycin for treatment of
MRSA infection is superior to the administration of vancomy-
cin alone [95,105]. Some results even suggest that the poten-
tial for hepatotoxicity, drug–drug interactions and the
emergence of antimicrobial-resistant S. aureus isolates war-
rants a careful risk–benefit assessment before addition of
rifampin to standard antibiotic treatment of severe S. aureus
infections [96,106].
A single dose or a very short course of gentamicin added
to vancomycin may be of use to maximize synergistic and
bactericidal activity and to minimize toxicity, according to dif-
ferent models, against isolates of S. aureus with a gentamicin
MIC of <500 lg/mL, but not in highly gentamicin-resistant
isolates [90,107–110]. In any case, vancomycin and gentami-
cin should be used carefully in patients with MRSA infections,
and for a very short period of time, in order to avoid neph-
rotoxicity [111–118]. The combination of fusidic acid with
rifampin or b-lactams may be synergistic in certain situations,
and this appears to be associated with lower rates of devel-
opment of fusidic acid resistance [119–121]. Clinical data to
support the use of fusidic acid in combination with either
b-lactams or glycopeptides for the treatment of staphylococ-
cal bacteraemia, endocarditis and osteomyelitis are very lim-
ited [122,123]. However, there is significantly less
development of resistance to fusidic acid when the drug is
used in combination with other agents [124,125]. Combina-
tions of fosfomycin with b-lactam drugs, arbekacin or other
drugs have shown in vitro and in vivo synergy against MRSA,
and these are combinations that warrant further investigation
[126–130]. The combination of daptomycin and rifampin can
be synergistic and improve results in the treatment of pros-
thetic joint infections [92]. The combination of vancomycin
and linezolid should be avoided [131].
Responses. The combination of glycopeptide with rifampicin
or fusidic acid was selected by the majority of the faculty
members (78%) and ECCMID delegates (60%) who would
consider using combination therapy to treat MRSA infection
(Table 5). Other combinations were selected less frequently
or not at all.
Conclusions. A wide variety of combinations are used, the
most popular ones being a glycopeptide with an aminoglyco-
side, rifampicin, or fusidic acid. There were a variety of cited
opinions on the advantages (increased efficacy and decreased
development of resistance) and disadvantages (increased tox-
icity) of combination therapy, but there is little published evi-
dence to support combination therapy over monotherapy.
Further research is required on older antibiotics and combi-
nations in this clinical area.
Treatment of complicated SSTIs
Question 19. For a complicated skin and soft tissue infection
caused by MRSA, what would be your initial IV treatment?
Background. The choice of antimicrobial agents for MRSA
complicated SSTIs is based on various clinical considerations:
disease severity, care setting (hospital vs. community), previ-
ous treatment, previous drug failure, and possible switch to
oral drugs [132]. There are five antibiotics approved by the
European Medicines Agency (EMEA) for the treatment of
complicated SSTIs due to MRSA: vancomycin, teicoplanin, lin-
ezolid, daptomycin, and tigecycline. All of these agents are
also approved for use by the US Food and Drug Administra-
tion, with the exception of teicoplanin; and all of them are
reported in the Infectious Diseases Society of America guide-
line for management of SSTIs—with the exception of tigecy-
cline, which was not available in 2005 when the guidelines
were published [6]. Various other agents may also be suit-
able for IV treatment, either alone or in combination, and
depending on susceptibility. These include clindamycin, co-
trimoxazole, rifampicin, fusidic acid, and aminoglycosides.
Responses. IV vancomycin, selected by 46% of the faculty
members and 59% of the ECCMID delegates, is the standard
treatment for MRSA complicated SSTIs in the hospital setting
(Fig. 11). In some European countries, such as Italy and Turkey,
teicoplanin is the preferred glycopeptide, as reflected in the
survey results. However, escalation of vancomycin MICs is a
cause for concern [133], and vancomycin is increasingly being
linked with clinical failures. IV linezolid, selected by 23% of the
faculty members and 11% of the ECCMID delegates, has been
shown to be comparable to vancomycin for the treatment of
complicated SSTIs due to MRSA [134,135]. ECCMID delegates
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also selected daptomycin and tigecycline as choices for the ini-
tial IV treatment of complicated SSTIs due to MRSA. However,
none of the faculty members chose tigecycline.
Conclusions. Glycopeptides, linezolid and daptomycin are
considered to be suitable agents for the initial IV treatment
of complicated SSTIs caused by MRSA. Tigecycline is also
approved by the EMEA for the treatment of complicated
SSTIs caused by MRSA; it was, however, chosen less fre-
quently by ECCMID delegates specifically for MRSA compli-
cated SSSIs, perhaps because of its broader spectrum and
because faculty members and ECCMID delegates may have
had limited clinical experience with tigecycline.
Question 20. Assuming that the causative strain of MRSA is
susceptible to the drug, what would you use for early oral
switch in patients with complicated skin and soft tissue
infection?
Background. Despite the high prevalence of complicated
SSTIs, there are relatively few randomized controlled studies
addressing the oral antibiotic treatment of complicated SSTIs
caused by MRSA. More reliable information is available on
newer antibiotics such as linezolid and long-acting tetracy-
clines [136–138]. Before the advent of CA-MRSA, trimetho-
prim–sulphamethoxazole was rarely used for treatment of
skin infections, because of poor activity against group A
streptococci [139]. Clindamycin is a good option for SSTIs
caused by MRSA strains susceptible to this drug [140], but
there are concerns that rates of resistance to clindamycin
can be underestimated if testing for inducible macrolide–lin-
cosamide–streptogramin B resistance is not performed
[141]. For the treatment of erythromycin susceptible MRSA
strains, clindamycin is a preferred choice as emergence of
clindamycin resistance requires two step mutation and its
bioavailability is better [32]. Fluoroquinolones are not
recommended for the treatment of MRSA infections, as even
sensitive isolates may rapidly develop resistance to these
agents [13,142]. A good overview of the clinical evidence
base for using oral antibiotics for the treatment of SSTIs
caused by MRSA is published by Enoch et al. [142].
Responses. Linezolid was the most common choice for
early oral switch in the treatment of complicated SSTIs due
to MRSA, being selected by the majority (67%) of the faculty
members and 25% of the ECCMID delegates (Fig. 12). Clin-
damycin plus rifampicin and trimethoprim–sulphamethoxaz-
ole were also selected by about 10–25% of the faculty
members and ECCMID delegates. A small minority (5%) of
the ECCMID delegates responded that they would not
switch to oral treatment for complicated SSTIs due to
MRSA.
Conclusions. Linezolid is considered to be the most appro-
priate agent for early oral switch in complicated SSTIs due
to MRSA. Older antistaphylococcal agents may be effective
(especially in cases of CA-MRSA), but more controlled stud-
ies with these agents are needed.
Treatment of minor skin infections
Question 21. For minor infection of soft tissue caused by
MRSA and not requiring hospitalization, what antibiotic
would you choose?
Background. SSTIs are the most common manifestations of
infections caused by CA-MRSA. HA-MRSA is also a frequent
cause of hospital-acquired SSTIs, but care should be taken to
distinguish MRSA wound colonization from infection, as
FIG. 11. For a complicated skin and soft tissue infection caused by
MRSA, what would be your initial IV treatment? (Question 19.)
ECCMID, European Congress of Clinical Microbiology and Infectious
Diseases; IV, intravenous; MRSA, methicillin-resistant Staphylococcus
aureus.
FIG. 12. Assuming that the causative strain of MRSA is susceptible
to the drug, what would you use for early oral switch in patients
with complicated skin and soft tissue infection? (Question 20.) ECC-
MID, European Congress of Clinical Microbiology and Infectious Dis-
eases; MRSA, methicillin-resistant Staphylococcus aureus.
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excessive and inappropriate use of antibiotics may lead to
selection of even more resistant bacteria [33]. The use of anti-
biotics is also not justified in minor community-acquired SSTIs
or small abscesses, even if they are caused by MRSA [13].
There was no difference in clinical outcome among groups of
patients with CA-MRSA SSTIs who were treated with appro-
priate or inappropriate (b-lactam) antibiotic therapy [143].
However, in patients who have larger lesions (infection site
>5 cm in diameter), systemic signs of infection, or nose or
face involvement, or in whom incision and drainage alone have
failed to cure the infection, systemic antibiotics should be
administered.
Responses. There was little consensus on the antibiotic of
choice for the treatment of minor SSTIs due to MRSA; 8%
of the faculty members and 23% of the ECCMID delegates
indicated that they would not use antibiotics, but would treat
only with drainage, if required, and dressings (Fig. 13). For
participants who would use antibiotics, the most commonly
selected treatment was trimethoprim–sulphamethoxazole,
followed by doxycycline monotherapy, clindamycin plus rif-
ampicin, and doxycycline plus rifampicin or fusidic acid.
Conclusions. A variety of agents are suitable for the treat-
ment of CA-MRSA minor skin infections where drainage
alone is insufficient. These include co-trimoxazole (trimetho-
prim-sulphamethoxazole), clindamycin, doxycycline as mono-
therapy, or doxycycline in combination with rifampicin or
fusidic acid. Local susceptibility testing must be taken into
account.
MRSA colonization
Question 22. Are systemic antibiotics ever justified for
clearing MRSA carriage?
Background. This survey has not closely examined the
important issue of MRSA carriage, screening, and decoloniza-
tion. Colonization with MRSA has implications with regard
to transmission and infection control, and is a risk factor for
subsequent clinical infection. It is usually desirable to elimi-
nate carriage of MRSA when detected, and this is best
achieved with topical agents such as mupirocin. Use of sys-
temic antibiotics should be considered only when there is a
serious clinical reason for clearing colonization and when
topical agents fail [144,145]. Although any use of systemic
antibiotics carries the risk of development of resistance and
side effects, decolonization treatment using systemic antibiot-
ics in complicated carriers is, in general, short (5–7 days),
and has not yet been associated with resistance develop-
ment, when applied as outlined in a recent Dutch guideline
[146].
Responses. There was disagreement between the faculty
members and the ECCMID delegates with respect to the
use of systemic antibiotics for clearance of MRSA coloniza-
tion (Table 6). The majority of the faculty members (69%)
indicated that the use of systemic antibiotics may be justified
in certain cases, as compared with only 31% of the ECCMID
delegates.
Conclusions. Systemic antibiotics are rarely, if ever, justified
for eliminating MRSA colonization. Antibiotics are only justi-
fied for eliminating MRSA colonization in complicated cases
(e.g. failure after topical treatment) and after consultation
with an infection specialist.
Question 23. Should topical decolonization treatments be
included for patients being treated with systemic antibiotics
for MRSA infection?
Background. On the basis that the carriage of MRSA
presents risks related to infection control, transmission to
FIG. 13. For minor infection of soft tissue caused by MRSA and not
requiring hospitalization, what antibiotic would you choose? (Ques-
tion 21.) ECCMID, European Congress of Clinical Microbiology and
Infectious Diseases; MRSA, methicillin-resistant Staphylococcus aureus.
TABLE 6. Antibiotic treatment of methicillin-resistant







Are systemic antibiotics ever
justified for clearing MRSA carriage?
N = 13 N = 255
Yes 9 (69) 80 (31)
No 4 (31) 175 (69)
Should topical decolonization
treatments be included for patients
being treated with systemic antibiotics
for MRSA infection?
N = 13 N = 253
Yes 9 (69) 177 (70)
No 4 (31) 76 (30)
ECCMID, European Congress of Clinical Microbiology and Infectious Diseases.
CMI Dryden et al. Antibiotic management of MRSA: a European survey 17
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16 (Suppl. 1), 3–30
others, and infection of the individual patient, it is logical to
screen superficial sites of patients with significant MRSA
infection and attempt to clear carriage with topical antimi-
crobials such as nasal mupirocin while systemic treatment is
being administered for the infection [147].
Responses. The majority of the faculty members (69%) and
ECCMID delegates (70%) agreed that topical decolonization
treatments should be included for patients being treated with
systemic antibiotics for MRSA infection (Table 6).
Conclusions. Attempts should be made with topical treat-
ments to decolonize patients being treated for MRSA infection,
in order to avoid re-infection, as not all antistaphylococcal
agents will lead to eradication of MRSA on the mucous mem-
branes, and to avoid further transmission from superficial body
surfaces to patients, staff, or the environment.
Treatment of bacteraemia
Question 24. For a confirmed MRSA bacteraemia, what is
your (a) first-line and (b) second-line treatment?
Background. The successful management of MRSA bactera-
emia depends on determining the extent of the infection and
on making appropriate decisions about the type and length of
therapy [148]. The antimicrobial agents available in Europe for
the treatment of complicated and uncomplicated MRSA bac-
teraemia are: vancomycin, teicoplanin, linezolid, tigecycline,
daptomycin, quinupristin–dalfopristin, co-trimoxazole, and
clindamycin. The usual treatment for MRSA bacteraemia is IV
vancomycin. This antibiotic is available only in IV form, and has
the potential for toxicity. Teicoplanin is available in both IV
and intramuscular formulations. The majority of new
compounds are available only in IV formulations (daptomycin,
tigecycline, and quinupristin–dalfopristin). The one exception
to this is linezolid, which is equally active in its IV and oral for-
mulations. Co-trimoxazole and clindamycin are also available
in IV and oral formulations, and have excellent bioavailability.
Responses. Vancomycin was the preferred first-line treat-
ment and linezolid the preferred second-line treatment for
bacteraemia due to confirmed MRSA infection (Fig. 14). Dap-
tomycin was selected as a first-line or second-line treatment
by some of the faculty members and ECCMID delegates. Tei-
coplanin, tigecycline, quinupristin–dalfopristin and glycopeptide
combination therapy were each selected as choices for first-
line or second-line treatment by a minority of participants.
Conclusions. Glycopeptides are currently the most favoured
first-line agents for treatment of MRSA bacteraemia, with lin-
ezolid and daptomycin as close second-line agents.
Treatment of pneumonia
Question 25. Should all patients with a clinical suspicion of
healthcare-associated pneumonia/hospital-acquired pneumo-
nia/ventilator-associated pneumonia (HCAP/HAP/VAP) be
treated with an antimicrobial agent active against MRSA?
Background. Failure to initiate prompt, appropriate and ade-
quate therapy (that is, the aetiological organism is sensitive
to the therapeutic agent, the dose is optimal, and the correct
route of administration is used) has been a crucial factor
consistently associated with increased mortality and morbid-
ity in patients with HCAP/HAP/VAP [50,61,149–152].
However, appropriate initial therapy should be achieved
without the overuse and abuse of antibiotics [50,56,57,153].
This requires that the choice be driven by anticipation of the
likely aetiological pathogens, modified by knowledge of local
patterns of antimicrobial resistance and local microbiology.
Having a current and frequently updated knowledge of local
bacteriological patterns at the ICU level, as well as at the
patient level, can increase the likelihood that appropriate ini-
tial antibiotic treatment will be prescribed [154–157]. Several
recent studies have documented that early-onset infection in
the ICU can be caused by MRSA, and that the concept of
early-onset and late-onset pathogens is no longer helpful for
the management of empirical antibiotic therapy in many ICUs
[158–161]. The time of onset of infection is only one of the
key variables associated with multiresistant pathogens
(a)
(b)
FIG. 14. For a confirmed MRSA bacteraemia, what is your (a) first-
line and (b) second-line treatment? (Question 24.) ECCMID, Euro-
pean Congress of Clinical Microbiology and Infectious Diseases;
MRSA, methicillin-resistant Staphylococcus aureus.
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[47,162–166]. Therefore, decision trees for selecting initial
therapy in patients with VAP should integrate not only the
timing of onset of infection but also other specific risk fac-
tors for multiresistant microorganisms, such as previous con-
tact with the healthcare system or recent prolonged
antibiotic therapy. At the present time, most experts recom-
mend that, in countries with a low or relatively low (<20%)
prevalence of MRSA, patients with early-onset infection and
no specific risk factors, such as MRSA nasal carriage, admis-
sion from a healthcare-related facility, or recent prolonged
antibiotic therapy, be treated with a narrow-spectrum drug
that is not active against MRSA [12,50,52,53,153].
Responses. In accordance with current expert opinion, the
majority of the faculty members and ECCMID delegates dis-
agreed with the statement that all patients with a clinical sus-
picion of HCAP/HAP/VAP should be treated with an
antimicrobial agent active against MRSA (Table 7).
Conclusions. As it is not considered appropriate to treat all
patients with a clinical suspicion of HCAP/HAP/VAP with an
antimicrobial agent active against MRSA, empirical treatment
should follow hospital antibiotic guidelines developed on the
basis of local epidemiology and susceptibility data.
Question 26. If the answer to the question above is no,
which patients with a clinical suspicion of HCAP/HAP/VAP
should be treated with an antimicrobial agent active against
MRSA? (Check all that apply.)
Background. Underlying diseases and specific risk factors
may predispose patients to infection with MRSA, as may
some intrinsic factors linked to each hospital or ICU
[47,50,159,162–167]. Therefore, selection of initial antimicro-
bial treatment needs to be tailored to each institution’s local
patterns of antimicrobial resistance [164,166,167]. Specific
risk factors for the development of MRSA VAP include
prior colonization or infection by MRSA [168–172], prior
prolonged antimicrobial treatment [164,166,173,174], prior
hospitalization in high-risk settings, such as nursing homes
with high (>20%) local MRSA prevalence [165], and late-
onset infection when ICU MRSA prevalence is high (>20%)
[166,175]. As compared with colonization with MSSA, MRSA
was associated with a four-fold to ten-fold increased risk of
infection, including pneumonia [168,170,171]. The type of
antibiotic exposure may also play a role, with a significant
association between total inpatient fluoroquinolone and/or
third-generation cephalosporin use and percentage of MRSA
isolated having been shown [173,174,176,177]. The presence
of more than two patients with nasal MRSA colonization in
the same ICU at the same time or breaches in infection con-
trol measures, such as non-compliance with hand hygiene
(disinfection and washing) and isolation precaution recom-
mendations, have also been linked to increased frequencies
of MRSA infections [178,179]. Although precise thresholds
have not been established, it seems prudent to prescribe an
agent effective against MRSA to patients who have presumed
severe staphylococcal infections in settings where the preva-
lence of MRSA is known to be >20%.
Responses. Participants who answered no to Question 25
were asked to consider which patients with a clinical sus-
picion of HCAP/HAP/VAP should be treated empirically
with an antimicrobial agent active against MRSA (Table 7).
The majority of the faculty members and ECCMID dele-
gates (53–75%) agreed that empirical antimicrobial therapy
against MRSA could be initiated for patients previously
identified as being colonized or infected by MRSA, patients
with prior hospitalization in high-risk settings, such as
nursing homes with high (>20%) local MRSA prevalence,
and patients with late-onset infection or prior antimicrobial
treatment when ICU MRSA prevalence is high (>20%).
Patients with MRSA present in the nasopharynx were also con-
sidered to be candidates for empirical anti-MRSA therapy by
61% of the ECCMID delegates. Of the ECCMID delegates, 18%
indicated that they would not empirically treat for MRSA infec-
tion in any of the patient groups listed above, but would wait
TABLE 7. Empirical treatment of healthcare-associated
pneumonia (HCAP)/hospital-acquired pneumonia (HAP)








Should all patients with a clinical suspicion
of healthcare-associated pneumonia/hospital-
acquired pneumonia/ventilator-associated
pneumonia (HCAP/HAP/VAP) be treated
with an antimicrobial agent active against
MRSA?
N = 13 N = 251
Yes 4 (31) 42 (17)
No 9 (69) 209 (83)
If the answer to the question above is no,
which patients with a clinical suspicion of
HCAP/HAP/VAP should be treated with
an antimicrobial agent active against MRSA?
(Check all that apply)
N = 9 N = 215
Patients previously identified as being
colonized or infected by MRSA
2 (22) 161 (75)
Patients with prior hospitalization in high-
risk settings such as nursing homes with high
(>20%) local MRSA prevalence
0 114 (53)
Patients with late-onset infection and/or
prior antimicrobial treatment when ICU
MRSA prevalence is high (>20%)
1 (11) 125 (58)
ECCMID survey only: patients with MRSA
present in the nasopharynx
– 132 (61)
Faculty survey only: all of the above 6 (67) –
None of the above. Wait for culture results 0 38 (18)
ECCMID, European Congress of Clinical Microbiology and Infectious Diseases;
ICU, intensive-care unit; MRSA, methicillin-resistant Staphylococcus aureus.
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for positive culture results before prescribing an anti-MRSA
agent.
Conclusions. Patients with a clinical suspicion of HCAP/HAP/
VAP should be treated with an antimicrobial agent active
against MRSA if they are colonized with MRSA in the naso-
pharynx. In addition, the other risk factors listed above should
prompt strong consideration of treatment covering MRSA.
Question 27. When MRSA pneumonia (HCAP/HAP/VAP) is
confirmed, what do you regard as the most appropriate
treatment regimen?
Background. Current management guidelines recommend
glycopeptides as initial therapy for MRSA VAP
[12,50,52,53,153]. However, vancomycin success rates in
patients with MRSA pneumonia are low, not exceeding 65%
[48,180–182]. This may be due to the poor penetration of
vancomycin into the lung, in particular when conventional,
low-dose regimens of this drug are used [54,55]. In serial
quantitative cultures, only 15% of patients with MRSA VAP
treated with vancomycin demonstrated decreased colony
counts below diagnostic thresholds [183]. This failure to
clear the bacteria within the first several days of treatment
was associated with increased 28-day mortality [183]. Clinical
experience to date suggests that patients with high serum
vancomycin area under the curve divided by MIC have better
outcomes than those with lower area under the curve/MIC
[184,185]. However, vancomycin given at the dosages neces-
sary to achieve such levels may be associated with renal dys-
function, especially when given concomitantly with other
nephrotoxic drugs [186,187].
Linezolid is an alternative to vancomycin for the treatment
of MRSA VAP, and may be preferred on the basis of its bet-
ter pulmonary penetration [49,182,188–193]. Combination
of data from a subset analysis of two prospective randomized
trials comparing linezolid with vancomycin for the treatment
of suspected Gram-positive nosocomial pneumonia to evalu-
ate the subset of patients with MRSA pneumonia revealed
significantly higher clinical cure rates with linezolid than with
vancomycin (59% vs. 35%) [189,193]. Logistic regression
analysis of MRSA VAP specifically confirmed that linezolid
treatment remained a significant predictor of clinical cure.
This analysis, however, was criticized on methodological
grounds, because of a non-prespecified subgroup analysis,
the heterogeneity of results in the separate studies, and the
small numbers of patients infected with MRSA. Linezolid was
equivalent to vancomycin and teicoplanin for a variety of
other MRSA infections in randomized, open-label trials
[191,194,195]. On the basis of this, linezolid may be pre-
ferred for the treatment of MRSA pneumonia if patients have
renal insufficiency or are receiving other nephrotoxic agents,
or when infection is caused by a strain with a vancomycin
MIC ‡1.5 lg/mL [50,196].
Patients with recurrent MRSA infection or with a history
of extended vancomycin exposure should be considered to
be at high risk of infection with MRSA strains for which
vancomycin MICs are elevated. Appropriate and aggressive
empirical therapy is required for these patients, and this can
justify a preference for linezolid [197]. Quinupristin–dalfopri-
stin demonstrated overall lack of efficacy as compared with
vancomycin in two studies, thus limiting its use for MRSA
infections [181,198]. Similarly, daptomycin was found to be
inferior to a cephalosporin for community-acquired pneumo-
nia [199]. In addition to poor penetration into lung tissue,
because of its large molecular size, in vitro data suggest that
daptomycin is inactivated by surfactant, making it an inappro-
priate choice for MRSA pneumonia [200–202]. Tigecycline is
approved for complicated skin and intra-abdominal infec-
tions, including those caused by MRSA [203,204]. In vitro data
suggest activity for MRSA, but data for clinical efficacy are
lacking.
Responses. Linezolid was considered to be the most appro-
priate regimen for treatment of HCAP/HAP/VAP due to
confirmed MRSA by 69% of the faculty members and 46% of
the ECCMID delegates (Fig. 15). Vancomycin was considered
to be the most appropriate regimen by 31% of the faculty
members and 45% of the ECCMID delegates.
Conclusions. Linezolid and vancomycin were considered to
be the most appropriate agents for treatment of HCAP/
HAP/VAP due to confirmed MRSA.
Treatment of patients infected by MRSA strains with reduced
vancomycin susceptibility
Question 28. Do you use the glycopeptide minimum inhibi-
tory concentration (MIC) routinely to guide your choice of
treatment?
Background. There appears to have been a slow shift (‘MIC
creep’) in vancomycin MICs in a number of centres
[133,205,206]. Much of this MIC creep has been within the
MIC ranges generally regarded as indicating susceptibility, but
there is increasing concern that rising vancomycin MICs are
associated with a poorer prognosis. Infections caused by
strains with higher vancomycin MICs are more likely to fail
to respond to vancomycin treatment [207], with a failure
rate of 48% at an MIC of 0.5 mg/L, as compared with a fail-
ure rate of 92% at an MIC of 2 mg/L.
Heterogeneous populations of S. aureus with an overall
susceptibility to vancomycin (heterogeneous vancomycin-
intermediate S. aureus (hVISA)); MIC <2 mg/L) but with non-
susceptible subpopulations are probably precursors of
S. aureus strains with intermediate vancomycin resistance
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(vancomycin-intermediate S. aureus (VISA)) [208,209]. True
vancomycin resistance remains rare, but is difficult to detect,
and could become more widespread [210,211]. Therefore,
measuring the vancomycin/glycopeptide MIC of S. aureus
causing serious infection is important, as it may influence
outcome in individual cases, and it is important to monitor
temporal trends in MIC.
Responses. Approximately half of the ECCMID delegates
and 85% of the faculty members indicated that they routinely
use glycopeptide MIC levels to guide their choice of treat-
ment for serious MRSA infections (Fig. 16).
Conclusions. Strains of MRSA causing serious infection
should have a vancomycin/glycopeptide MIC measured to
guide the choice of treatment.
Question 29. At which vancomycin MIC level for MRSA (by
Etest) would you replace vancomycin with an alternative antibi-
otic?
Background. For decades, glycopeptides have been the refer-
ence standard therapy for MRSA infections. With MIC creep,
VISA, hVISA and vancomycin-resistant S. aureus, the measure-
ment of vancomycin MIC in strains causing serious infection is
important. Where the vancomycin MIC is >1 mg/L, alternative
antibiotics should be sought [212].
It should be noted, however, that interpretation of vanco-
mycin MICs is dependent on the laboratory method used to
detect resistance. Many laboratories commonly use the stan-
dard Etest or MIC broth dilution, to which values reported in
this article refer. However, it is generally believed that VISA
strains can best be detected by the Etest macro method
[213]. The Etest macro method uses a higher inoculum
(2.0 mg/mL McFarland), richer agar medium (brain–heart
infusion) and a longer incubation time (48 h) than the
standard Etest method, and vancomycin and teicoplanin
values ‡8 mg/L are indicative of reduced susceptibility to gly-
copeptides.
Responses. There was a lack of consensus between the
faculty members and ECCMID delegates regarding the MRSA
MIC level at which to replace vancomycin with an alternative
antibiotic; however, the majority chose either 1.5 or 2.0 mg/L
as the cut-off point (Fig. 17). Interestingly, an additional 18%
of ECCMID delegates indicated that they would use an alter-
native antibiotic for the treatment of MRSA infection in
patients infected by strains with an MIC level of 1.0 mg/L.
Conclusions. At a vancomycin MIC of ‡1.5 mg/L as deter-
mined by Etest, alternative therapy should be considered.
Question 30. What do you regard as the most appropriate
anti-MRSA agent for the treatment of serious MRSA infec-
tion in patients infected by strains with reduced vancomycin
susceptibility?
Background. A severe infection potentially caused by MRSA,
particularly in epidemiological conditions in which the MRSA
vancomycin MIC is frequently >1.5 mg/L, should not be
empirically treated with vancomycin if alternatives such as
linezolid or daptomycin are available [14]. Linezolid is the
drug of choice for the treatment of MRSA pneumonia and
MRSA infections of the central nervous system
[79,182,189,214–219]. Both daptomycin and linezolid are
probably equivalent alternatives for the treatment of compli-
cated SSTIs caused by MRSA [194,220–226]. Daptomycin is
the drug of choice for the treatment of primary bacteraemia
FIG. 15.When MRSA pneumonia (HCAP/HAP/VAP) is confirmed,
what do you regard as the most appropriate treatment regimen?
(Question 27.) ECCMID, European Congress of Clinical Microbiol-
ogy and Infectious Diseases; HAP, hospital-acquired pneumonia;
HCAP, healthcare-associated pneumonia; MRSA, methicillin-resistant
Staphylococcus aureus; VAP, ventilator-associated pneumonia.
FIG. 16. Do you use the glycopeptide minimum inhibitory concen-
tration (MIC) routinely to guide your choice of treatment? (Ques-
tion 28.) ECCMID, European Congress of Clinical Microbiology and
Infectious Diseases.
CMI Dryden et al. Antibiotic management of MRSA: a European survey 21
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16 (Suppl. 1), 3–30
or bacteraemia originating in a catheter infection and in
endocarditis [94]. Tigecycline can be used for the treatment
of polymicrobial intra-abdominal infections when MRSA is
among the causative microorganisms [203].
Responses. Linezolid was selected by 61% of faculty mem-
bers and ECCMID delegates as the most appropriate choice
for the treatment of serious MRSA infections in patients
infected by strains with reduced susceptibility to vancomycin
(Fig. 18). Daptomycin was selected by 23% of the faculty
members and ECCMID delegates, whereas a smaller percent-
age (<15%) preferred either tigecycline, teicoplanin, or
another antibiotic.
Conclusions. The choice of anti-MRSA agent depends on
the infection in question but, in general, linezolid or dapto-
mycin is the most appropriate agent for the treatment of
MRSA infection in patients infected by strains with reduced
vancomycin susceptibility.
Summary
The results of this large ECCMID survey add further weight
to our understanding of the opinions and practical experi-
ence of European clinicians in the management of MRSA
infections. This has been an important survey for the review
of areas of practice for which there is little clinical evidence,
guidance of further research, and support of management
guidelines. The epidemiology of MRSA infection varies across
Europe and is continually evolving. In many areas, HA-MRSA
infection is decreasing, but it is still common. Inevitably,
there are differences in opinion and practice across such a
wide geographical area with varied epidemiology; neverthe-
less, some common themes are apparent.
For the control of HCA-MRSA infection, common issues
were that MRSA colonization of the individual patient or
associated patients was a major risk factor for infection, and
the most common infections arose from intravascular lines
or soft tissue/surgical infection. There are therefore two
main areas of intervention that, if implemented across Eur-
ope, would probably help to reduce HCA-MRSA infection
further. These are, first, improved care of intravascular lines
and their timely removal and, second, screening surgical
patients—and possibly all hospitalized patients—for MRSA
and, if positive, decolonization.
The survey identified a broad range of opinions regarding
the empirical treatment of MRSA infections. A significant
proportion of respondents would have given systemic anti-
biotics in clinical situations where MRSA was a colonizer
rather than an infecting pathogen—such as in colonized
catheter urine, respiratory secretions, or superficial skin
ulcers. In principle, this should be discouraged in favour of
establishing a policy requiring clear clinical evidence of
infection before systemic antibiotics are administered. In
relation to this, the survey found that a small number of
respondents were prepared to use systemic antibiotics to
clear carriage in special clinical cases; however, again, this
practice should be discouraged. Most respondents considered
previous colonization with MRSA to be the major risk factor
for MRSA infection, thus again pointing towards screening
and decolonization as a means of reducing infection.
There was consensus of opinion on some key aspects of
the management of infections due to MRSA, including pre-
ferred antibacterial treatments for MRSA pneumonia and
FIG. 17. At which vancomycin MIC level for MRSA (by Etest) would
you replace vancomycin with an alternative antibiotic? (Question 29.)
ECCMID, European Congress of Clinical Microbiology and Infectious
Diseases; MRSA, methicillin-resistant Staphylococcus aureus.
FIG. 18.What do you regard as the most appropriate anti-MRSA
agent for the treatment of serious MRSA infection in patients
infected by strains with reduced vancomycin susceptibility? (Ques-
tion 30.) ECCMID, European Congress of Clinical Microbiology and
Infectious Diseases; MRSA, methicillin-resistant Staphylococcus aureus.
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MRSA bacteraemia. Although glycopeptides remain the drugs
of choice for most serious MRSA infections, the responses in
this survey—along with consensus statements, evidence-
based reviews, and guidelines—all reflect emerging concerns
about the effectiveness of glycopeptide use in treating seri-
ous MRSA infections, and the importance of identifying
where alternative therapies should be considered [5,8,16].
To optimize therapy, therapeutic drug monitoring of glyco-
peptides is recommended for all patients. However, the fre-
quency of sampling and the need for dose adjustments varies
between patient groups. If there are no underlying diseases
and treatment is relatively short, one trough sample may suf-
fice to improve efficacy [227]. Favoured alternative treat-
ments were reported as linezolid and daptomycin, with the
former being favoured for pneumonia and the latter being
marginally favoured for bacteraemia. Various combination
therapies were widely used; as evidence is often lacking, this
is an area for further research.
There was also a broad awareness of glycopeptide MIC
creep, with a range of views as to which vancomycin MIC
level as determined by Etest was the cut-off for switching to
alternative therapy. An MIC level of ‡1.5 mg/L was the
favoured cut-off for considering alternative treatment.
Oral treatments and early oral switch for many MRSA
infections were perceived as appropriate clinical practice. A
wide range of oral agents was recorded by respondents,
probably reflecting differences in antibiotic susceptibility
across Europe. Linezolid and co-trimoxazole were the most
favoured, but many respondents used combinations of doxy-
cycline, rifampicin, fusidic acid and macrolides, clindamycin
and fluoroquinolones as guided by susceptibility. This is
another important area for further research, particularly in
establishing the efficacy and safety of older oral agents for
treating MRSA infections. These are often used in the
absence of a firm base of evidence, and often in the place of
newer agents, on economic grounds.
OPAT is another area with a need for further consensus
and guidance. The majority of respondents are unfamiliar
with its use or do not use it, preferring oral switch. The pre-
dominant clinical indications for its use appear to be bone
and joint infection and complicated soft tissue infection.
There was surprising variation among the ECCMID dele-
gates, but not among the faculty members, on the duration
of therapy for the serious MRSA infections of bacteraemia
and pneumonia. The consensus is that 10 days of treatment
is a minimum for both, with 14 days being preferred.
This survey has been complex to implement and interpret,
and has several limitations, particularly with regard to the
fact that the epidemiology of MRSA infection is so varied
across Europe. The targeted survey population comprised
registered delegates to a large European congress on
infectious diseases and, owing to the limited sampling frame,
potentially knowledgeable individuals may have been
excluded. Although response bias is inherent in any survey,
the ECCMID survey achieved a response rate of 13%, which
is similar to that of other Internet-based surveys [8]. Despite
this, it represents the largest European survey of its kind.
This survey has been successful in identifying areas where
practice can be improved, where urgent research is needed,
and where pan-European consensus of opinion, although
imperfect, could be applied to European guidelines for the
management of MRSA infection.
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